Ignite Creation Date:
2024-07-17 @ 11:13 AM
Last Modification Date:
2024-10-26 @ 3:32 PM
Study NCT ID:
NCT06469944
Status:
RECRUITING
Last Update Posted:
2024-06-24
First Post:
2024-06-17
Brief Title:
Substudy 06C A Study of Sacituzumab Tirumotecan MK-2870 With Pembrolizumab MK-3475 and Chemotherapy in Participants With First-Line Locally Advanced UnresectableMetastatic Gastroesophageal Adenocarcinoma MK-3475-06CKEYMAKER-U06
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC